Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

275
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
275
Depression: Overview01:18

Depression: Overview

277
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
277
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

168
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
168
Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

175
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
175
Depressive Disorders: Etiology01:27

Depressive Disorders: Etiology

140
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
140
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

576
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
576

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multicenter Study on Communication, Language and Speech in Italian Children with Cerebral Palsy-Survey, Assessement Protocols and Proposal for a Classification System.

Children (Basel, Switzerland)·2026
Same author

Artificial intelligence as a digital analytic third: the SADAR framework for reflective supervision in psychotherapy.

Frontiers in psychology·2026
Same author

The Somatic Rubber Hand Illusion does not modulate perceived hand position in children with severe visual impairments.

Scientific reports·2026
Same author

Core symptoms of PTSD across four millennia: a phenomenological and nosographic analysis - from ancient Mesopotamian texts to modern psychiatric classifications.

Medical humanities·2026
Same author

Eye Tracking for Rehabilitation and Training in Paediatric Neurodevelopmental Disorders: A Systematic Review.

Brain sciences·2026
Same author

Treatment-resistant depression: time to rethink current definitions and clinical practice.

Frontiers in psychiatry·2026

Related Experiment Video

Updated: Jul 20, 2025

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.7K

Difficult-To-Treat Depression. Scoping Review.

Walter Paganin1, Sabrina Signorini2, Antonio Sciarretta3

  • 1Psychiatrist-Psychotherapist-PhD Student in Neuroscience, Tor Vergata University, Rome, Italy, EU.

Clinical Neuropsychiatry
|July 31, 2023
PubMed
Summary

Difficult-to-treat depression (DTD) is a distinct clinical concept that expands on treatment-resistant depression (TRD). This review summarizes current understanding and highlights the need for further research into DTD pathophysiology and treatment.

Keywords:
classificationclinical managementdifficult-to-treat depressionreviewtreatment-resistant depression

More Related Videos

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.0K
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

95

Related Experiment Videos

Last Updated: Jul 20, 2025

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.7K
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.0K
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

95

Area of Science:

  • Psychiatry and Mental Health
  • Clinical Psychology
  • Neuroscience

Background:

  • Difficult-to-treat depression (DTD) is increasingly recognized as a distinct clinical entity.
  • Existing definitions of DTD, such as the 2020 consensus statement, describe it as depression causing significant burden despite standard treatment efforts.
  • Interventions for DTD require a comprehensive approach, addressing not only symptom control but also comorbidities, psychosocial functioning, and self-management.

Purpose of the Study:

  • To conduct a scoping review of the scientific literature on the pathophysiology and treatment of difficult-to-treat depression.
  • To clarify the current conceptualization of DTD and its distinction from treatment-resistant depression (TRD).
  • To identify contributions, concepts, theories, and gaps in the existing body of knowledge on DTD.

Main Methods:

  • A systematic literature search was performed across major databases: PubMed, Scopus, PsycINFO, Cochrane Library, and Open Grey.
  • The search focused on articles published between January 1, 2013, and March 1, 2023, related to difficult-to-treat depression.
  • Eligibility criteria were independently assessed by two researchers using a formal checklist, with further data evaluation for comprehensive articles.

Main Results:

  • The review identified a body of literature that offers a clearer definition of difficult-to-treat depression.
  • The findings provide insights into the clinical application and research perspectives of DTD.
  • The literature supports DTD as a theoretically and clinically useful conceptualization for complex depressive syndromes.

Conclusions:

  • Difficult-to-treat depression represents a significant conceptual shift, extending the model of treatment-resistant depression.
  • DTD offers clinicians and researchers updated criteria for assessment and intervention, focusing on a broader therapeutic response.
  • Further research, including randomized controlled trials and observational studies, is necessary to fully define and investigate DTD.